anti-Human CD79b Antibody | anti-CD79B antibody

Anti-Hu CD79b PE-Cy7

Cat. Num. AAA129228

• Gene Names: CD79B; B29; IGB; AGM6
• Reactivity: Human
• Applications: Flow Cytometry, Functional Assay
• Synonyms: CD79b; N/A; Anti-Hu CD79b PE-Cy7; CD79b molecule; BCR beta; Ig-beta; B29; IGB; anti-CD79B antibody

• Reactivity: Human
• Isotype: Mouse IgG1 kappa
• Clone Number: CB3-1
• Specificity: The mouse monoclonal antibody CB3-1 recognizes an extracellular epitope of CD79b (CD79 beta, Ig beta), an approximately 38 kDa component of B cell receptor (BCR) complex.
• Form/Format: PE-Cy7; Purified antibody is conjugated with activated tandem dye of R-phycoerythrin-cyanine 7 (PE-Cy7) under optimum conditions and unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.; Stabilizing phosphate buffe

• Applicable Applications for anti-CD79B antibody: FCM/FACS (Flow Cytometry)
• Immunogen: Fraction of Ig-associated molecules isolated from Ramos B cells
• Preparation and Storage: Store at 2-8 degree C. Protect from prolonged exposure to light. Do not freeze.

FCM/FACS (Flow Cytometry)

(Separation of human CD19 positive CD79a positive lymphocytes (red-filled) from CD19 negative CD79a negative lymphocytes (black-dashed) in flow cytometry analysis (surface staining) of human peripheral whole blood stained using anti-human CD79b (CB3-1) PE-Cy™7 antibody (4 ?l reagent / 100 ?l of peripheral whole blood).)

FCM/FACS (Flow Cytometry)

(Flow cytometry multicolor surface staining pattern of human lymphocytes using anti-human CD79b (CB3-1) PE-Cy™7 antibody (4 ?l reagent / 100 ?l of peripheral whole blood) and anti-human CD19 (LT19) APC antibody (10 ?l reagent / 100 ?l of peripheral whole blood).)

FCM/FACS (Flow Cytometry)

(Flow cytometry surface staining pattern of human peripheral whole blood stained using anti-human CD79b (CB3-1) PE-Cy™7 antibody (4 ?l reagent / 100 ?l of peripheral whole blood).)

Related Product Information for anti-CD79B antibody

CD79b (Ig beta, B29) forms disulfide-linked heterodimer with CD79a (Ig alpha, MB1). They both are transmembrane proteins with extended cytoplasmic domains containing immunoreceptor tyrosine activation motives (ITAMs), and together with cell surface immunoglobulin they constitute B-cell antigen-specific receptor (BCR). CD79a and b are the first components of BCR that are expressed developmentally. They appear on pro-B cells in association with the endoplasmic reticulum chaperone calnexin. Subsequently, in pre-B cells, CD79 heterodimer is associated with lambda5-VpreB surrogate immunoglobulin and later with antigen-specific surface immunoglobulins. CD79a/b complex interacts with Src-family tyrosine kinase Lyn, which phosphorylates its cytoplasmic ITAM motives to form docking sites for downstream signaling.

References

*Nakamura T, Kubagawa H, Cooper MD: Heterogeneity of immunoglobulin-associated molecules on human B cells identified by monoclonal antibodies. Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8522-6., URL: https://www.ncbi.nlm.nih.gov/pubmed/1382292,*Zheng B, Fuji RN, Elkins K, Yu SF, Fuh FK, Chuh J, Tan C, Hongo JA, Raab H, Kozak KR, Williams M, McDorman E, Eaton D, Ebens A, Polson AG: In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates. Mol Cancer Ther. 2009 Oct;8(10):2937-46., URL: https://www.ncbi.nlm.nih.gov/pubmed/19808977,*Garcia Vela J, Delgado I, Benito L, Monteserin M, Garcia Alonso L, Somolinos N, Andreu M, Oña F: CD79b expression in B cell chronic lymphocytic leukemia: its implication for minimal residual disease detection. Leukemia. 1999 Oct;13(10):1501-5., URL: https://www.ncbi.nlm.nih.gov/pubmed/10516749,*Rassenti LZ, Kipps TJ: Expression of Ig-beta (CD79b) by chronic lymphocytic leukemia B cells that lack immunoglobulin heavy-chain allelic exclusion. Blood. 2000 Apr 15;95(8):2725-7., URL: https://www.ncbi.nlm.nih.gov/pubmed/10753858,*Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, Elkins K, French D, Go MA, Jack A, Junutula JR, Koeppen H, Lau J, McBride J, Rawstron A, Shi X, Yu N, Yu SF, Yue P, Zheng B, Ebens A, Polson AG: Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. 2009 Sep 24;114(13):2721-9., URL: https://www.ncbi.nlm.nih.gov/pubmed/19633198,*Matutes E: New additions to antibody panels in the characterisation of chronic lymphoproliferative disorders. J Clin Pathol. 2002 Mar;55(3):180-3., URL: http://www.ncbi.nlm.nih.gov/pubmed/11896067,*D'Arena G, Cascavilla N, Musto P, Colella Bisogno R, Pistolese G, Carotenuto M: CD79b expression in B-cell chronic lymphocytic leukemia. Haematologica. 2000 May;85(5):556-7., URL: http://www.ncbi.nlm.nih.gov/pubmed/10800181,

NCBI and Uniprot Product Information

• NCBI GI #: 728994
• NCBI GeneID: 974
• UniProt Accession #: P40259; Q53FS2; Q9BU06
• Molecular Weight: 229
• NCBI Official Full Name: B-cell antigen receptor complex-associated protein beta chain
• NCBI Official Synonym Full Names: CD79b molecule, immunoglobulin-associated beta
• NCBI Official Symbol: CD79B
• NCBI Official Synonym Symbols: B29; IGB; AGM6
• NCBI Protein Information: B-cell antigen receptor complex-associated protein beta chain; Ig-beta; B-cell-specific glycoprotein B29; immunoglobulin-associated B29 protein; CD79b antigen (immunoglobulin-associated beta)
• UniProt Protein Name: B-cell antigen receptor complex-associated protein beta chain
• UniProt Gene Name: CD79B
• UniProt Synonym Gene Names: B29; IGB
• UniProt Entry Name: CD79B_HUMAN